Surrozen (Surrozen) Total Operating Expense : $38.77 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Surrozen Total Operating Expense?

Surrozen's Total Operating Expense for the three months ended in Mar. 2024 was $9.13 Mil. Surrozen's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was $38.77 Mil.

Surrozen Total Operating Expense Historical Data

The historical data trend for Surrozen's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Total Operating Expense Chart

Surrozen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Operating Expense

32.81

54.39

56.84

43.03

Surrozen Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Operating Expense	Get a 7-Day Free Trial										13.39	10.28	9.68	9.68	9.13

Surrozen Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $38.77 Mil.

Surrozen Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Surrozen's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Surrozen (Surrozen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZNW) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

SRZN:USA

Address

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.surrozen.com

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).